Major PBS listings for pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC), urothelial cancer and nivolumab (Opdivo) and ipilimumab (Yervoy) for malignant melanoma have been recommended by the Pharmaceutical Benefits Advisory Committee. At its July meeting the PBAC made a positive recommendation for an Authority Required (Streamlined) listing of pembrolizumab for the second line treatment ...
Oncology biologics get nod from PBAC
By Michael Woodhead
22 Aug 2018